Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02250638 · ClinicalTrials.gov registry record
Longitudinal Pancreatic Cancer Study
A clinical trial, sponsored by Fujirebio Diagnostics.
- Completed
- Registry status
- 140
- Enrollment target
NCT02250638: Completed study, sponsored by Fujirebio Diagnostics.
NCT02250638 is a clinical trial that has completed, run by Fujirebio Diagnostics. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02250638 has completed, sponsored by Fujirebio Diagnostics.
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
Study Summary
To obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of pancreatic cancer.
Interventions
- OTHER CA 19-9 Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2014-05 |
| Est. Completion | 2021-06-30 |
What the finished NCT02250638 record still lists
NCT02250638 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which CA 19-9 Assay is the first listed.
NCT02250638 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02250638 about?
NCT02250638 is a clinical study titled "Longitudinal Pancreatic Cancer Study". To obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of pancreatic cancer.
What is the current status of trial NCT02250638?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2014-05. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT02250638?
The interventions under investigation include: CA 19-9 Assay (OTHER).
Who is sponsoring clinical trial NCT02250638?
This trial is sponsored by Fujirebio Diagnostics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia